Associated clinical studies in COVID-19
The emergence of the novel coronavirus (SARS-CoV-2) in December 2019 caused a pandemic of a severe coronavirus disease, COVID-19, that has become the main focus of several research projects.
ISARIC has many member networks, who are involved in patient-based research, to generate an evidence-based response to COVID 19, and has also provided support to several clinical trials, some of which are mentioned below.
We thank our partners who are involved in COVID-19 research.
We welcome additional partners to collaborate in this effort and help grow the global effort to find treatment for COVID-19.
Observational Clinical Studies
PHOSP-COVID is a major UK research study into the long-term health impacts of COVID-19 on hospitalised patients and is led by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. Visit PHOSP-COVID webpage
CCA COVID-19 is a standalone mobile and desktop app that healthcare facilities not currently part of an existing registry network can use. It enables institutions to retain ownership of data and use it for local service evaluation, by capturing SARI case reports in a systematic and internationally comparable manner with rapid on-boarding for healthcare organisations with minimal IT infrastructure. Visit CCA website
Clinical Characterisation Protocol (CCP) - The Clinical Characterisation Protocol (CCP) is designed for any severe or potentially severe acute infection of public health interest. It is a standardised protocol that enables data and biological samples to be collected rapidly in a globally-harmonised manner. Visit the CCP page.
ECMOCARD (ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease) is a prospective/retrospective multi-centre observational study to characterise COVID-19 patients admitted to the intensive care unit (ICU). The COVID-19 Critical Care Consortium currently runs in more than 280 hospitals worldwide across 6 continents. The ECMOCARD case report form was built using the established online SPRINT-SARI data collection form. The original ambition of SPRINT-SARI – to provide research tools for the world in an outbreak, is being demonstrated in this global collaboration to understand COVID-19 in ICU patients. Visit ECMOCARD’s website
GenOMICC (Genetics Of Mortality In Critical Care) study aims to find the genes that cause susceptibility to critical illness with coronavirus, which may help to prioritise treatments to provide better patient care. Visit the GenOMICC website
ISARIC 4C (Coronavirus Clinical Characterisation Consortium) is a UK-wide consortium of doctors and scientists committed to answering urgent questions about COVID-19 quickly, openly, and for the benefit of all. For more information, visit the ISARIC 4C website.
Clinical Trials
COPCOV is focusing on determining whether chloroquine and hydroxychloroquine, drugs that have been used to treat malaria and a variety of rheumatological conditions, could be effective in preventing COVID-19. For more information, visit COPCOV’s website.
LOTUS China (Lopinavir Trial for Suppression of SARS-Cov-2 in China). The first randomised controlled trial of a possible treatment for COVID-19 using lopinavir-ritonavir. Read the full article on LOTUS China clinical trial.
RECOVERY TRIAL (Randomised Evaluation of COVID-19 Therapy) is testing some of the potential treatments that have been suggested for COVID-19. Visit RECOVERY’s webpage.
REMAP-CAP is a global network of leading experts, institutions and research networks aiming to evaluate several treatment options simultaneously and efficiently. More information can be found by visiting REMAP-CAP’s website.
Other Clinical Trials
DISCOVERY is a multi-centre open clinical trial to be conducted in various sites in Europe. It aims to assess the safety and efficacy of treatments of COVID-19 in hospitalized adults. Visit the discovery website.
SOLIDARITY is an international clinical trial to help find an effective treatment for COVID-19, launched by the World Health Organization and partners. It aims to compare four treatment options against standard of care, to assess their relative effectiveness against COVID-19. More information on solidarity can be found by visiting Solidarity’s website
ISARIC has been fundamental in creating a portfolio of resources, which investigators may use, in order to collect and store data in a standardised way. The tools and resources have been built and developed in collaboration with the member networks, and other key partners, some of which include the World Health Organisation. Some of the studies above are using these tools.